The trajectory of companies tied to the drug's past presents a challenging investment landscape. While the initial success generated substantial profits , generic alternatives have significantly diminished sales . Investing in associated pharmaceutical companies now requires a discerning assessment of proprietary rights , evolving healthcare shifts